Fungal Invasion May Drive Some Pancreatic Cancers

The finding could advance the prevention and treatment of pancreatic cancer, which is usually fatal because it's often detected too late.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 11 October 2019Source: The American Journal of SurgeryAuthor(s): Dhruv J. Patel, Waseem Lutfi, Patrick Sweigert, Emanuel Eguia, Gerard Abood, Lawrence Knab, Paul C. Kuo, Marshall S. BakerAbstractBackgroundPrior studies of adjuvant systemic therapy in pancreatic acinar cell carcinoma have been underpowered.MethodsWe queried the National Cancer Data Base to identify patients presenting with resectable (clinical stage I and II) acinar cell carcinoma between 2004 and 2015. Multivariable Cox Regression was used to evaluate the association between overall survival and systemic therapy.Results29...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
CONCLUSIONS: Increased expression of miR-233 was associated with CDDP resistance in pancreatic cancer cells. Inhibition of miR-223 expression upregulated FoxO3a expression, restrained pancreatic cancer cell proliferation, promoted cell apoptosis, and enhanced CDDP sensitivity in pancreatic cancer cells. PMID: 31599414 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 10 October 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Nicolas Williet, Jérôme Desrame, Pascal Artru, Emilie Soularue, Bertrand Le Roy, Julien TaiebSummaryBackgroundA combination of nab-paclitaxel plus gemcitabine (N + G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no publish...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
Leone Aglietta Surgical resection remains the only treatment that offers a potential chance of long-term survival. Unfortunately, about 80% of patients treated with curative intent will develop recurrence. Since 2001, adjuvant therapy with gemcitabine or 5-fluorouracyle was recommended. This approach allows a median overall survival (OS) of around 23 months, and 5-year survival of 22%. In recent years, two phase-3 trials investigating new chemotherapy regimens resulted in considerably improved survival times. The doublet gemcitabine–capecitabine has shown improvement in OS from 25.5 to 28 months (p = 0...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionAlteration in the cell cycle by means of different mechanisms such as inflammation, alteration in cell signaling, invasion and immune evasion, specific niche colonization, induction of DNA damage and mutation, expression of some microRNAs, and enhancing epigenetic effects are the most common mechanisms employed by bacterial species.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
AbstractPurposeDespite advances in various treatment modalities, surgical resection for pancreatic ductal adenocarcinoma (PDA) remains the only curative treatment. Data remains limited regarding survival rates for resectable PDA when managed by a multidisciplinary pancreas conference (MDPC). The aim of this study is to assess survival rates, identify significant predictors of mortality, and assess the benefits of adjuvant chemotherapy for resectable PDA following presentation at a MDPC.MethodsAll patients presented from April 2013 to August 2016 with resectable PDA were discussed at a MDPC at a tertiary care center and wer...
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Adjuvant therapy using S-1 is a cost-effective alternative compared to gemcitabine in patients with postoperative pancreatic cancer from the Chinese societal perspective. PMID: 31597496 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Conditions:   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreatic Cancer Intervention:   Drug: Talabostat Mesylate Sponsors:   BioXcel Therapeutics Inc;   IQVIA Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A study published in theAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, suggests a vaccine against digestive hormone, gastrin, could help slow the spread of pancreatic cancer.News Medical
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
Treatment with 9-ING-41 significantly increased pancreatic tumor cell killing when combined with chemotherapy in pre-clinical trials.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Cancer | Cancer & Oncology | Health | Pancreas | Pancreatic Cancer